Search Team

Search by Last Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
  • Overview
  • Insights

About Cheryl

Cheryl Wang’s intellectual property litigation practice spans a wide range of technology, including life sciences, pharmaceuticals, biotechnology, software, hardware, and medical devices. Ms. Wang has worked on a variety of technologies, including pharmaceutical formulations, antibodies, biologics, immunotherapy, CRISPR, sleep apnea devices, encryption hardware, and mobile data. Ms. Wang has experience from pre-suit diligence to dispositive hearing, including analyzing patent portfolios, conducting research and discovery, briefing injunctive and claim construction issues, assisting depositions and expert reports, and preparing witnesses for trial testimony. Ms. Wang has worked on U.S. district court, ITC, arbitration, and Federal Circuit cases.

Ms. Wang is committed to pro bono and diversity. She represents indigent pro bono clients and work on high-impact policy litigation.

Before joining Fish, Ms. Wang worked in nanotechnology and small molecule pharmaceutical development. She has also clerked for Judge Tamila E. Ipema and Judge Joel Pressman, and worked as a legal research specialist and treatise editor.

Selected Publications

Ms. Wang is a contributing author to Fish’s IP Law Essentials.

How Biosimilars Are Approved and Litigated: Patent Dance Timeline,” co-authored with Kayleigh McGlynn, Grant Rice, Jenny Shmuel, Nicole Williams, Fish IP Law Essentials Blog (August 12, 2020).

FDA Seeks to Modernize the Orange Book,” co-authored with Geoff Biegler and Megan Chacon, Fish Litigation Blog (June 22, 2020).

Introduction to Biologics and Biosimilars,” co-authored with Michael Anderson, Kayleigh McGlynn, Tracea Rice, Jenny Shmuel, Fish IP Law Essentials Blog (June 4, 2020).

Overview of Approaches to Compulsory Licensing,” co-authored with Brian Coggio and Sushil Iyer, Fish IP Law Essentials Blog (May 21, 2020).

Where Juries Come From,” co-authored with Alexander Kykta, Douglas McCann, Katherine Reardon, Fish IP Law Essentials Blog (May 1, 2020).

A Biosimilar’s Guide to the BPCIA Patent Dance: Five Key Questions for Every Biosimilar Applicant to Consider,” co-authored with Jenny Shmuel, Michael Anderson, Kayleigh McGlynn, Grant Rice, Fish Litigation Blog (April 20, 2020).

Insulin and Other Biological Products Previously Regulated as “Drugs” Transition to Biologics Regulation on March 23, 2020,” co-authored with Jenny Shmuel and Michael Anderson, Fish Litigation Blog (March 20, 2020).

Increasing Competition in the Biologic Market Through Truthful Advertising,” co-authored with Jenny Shmuel, Fish Litigation Blog (February 7, 2020).

Speaking Engagements

Protecting Your Trade Secrets from Misappropriation,” co-speaker, Fish Webinar (February 24, 2021).

Focus Areas
Education

J.D., University of Virginia School of Law (2018) Articles Editor, Virginia Tax Review


B.S., Chemistry with minor in Psychology, University of California, San Diego (2014)

Admissions
  • California 2018
Languages
  • English
  • Mandarin Chinese

What's trending with Cheryl

Filter by
Event
February 24th, 2021 | 1:30 pm EST
Webinar | Protecting Your Trade Secrets from Misappropriation
Webinar
Blog
August 12, 2020
How Biosimilars Are Approved and Litigated: Patent Dance Timeline
Authors: Kayleigh E. McGlynn, Cheryl Wang, Nicole Williams, Jenny Shmuel, Ph.D.
IP Law Essentials
Blog
July 10, 2020
Chief Judge Stark Dismisses Hatch-Waxman Case after Paragraph IV to Paragraph III Conversion
Authors: Cheryl Wang, Megan A. Chacon, Geoffrey D. Biegler
Legal Alerts
Blogs
Blog
June 22, 2020
FDA Seeks to Modernize the Orange Book
Authors: Cheryl Wang, Megan A. Chacon, Geoffrey D. Biegler
Blogs
Blog
June 4, 2020
Introduction to Biologics and Biosimilars
Authors: Kayleigh E. McGlynn, Tracea L. Rice, Cheryl Wang, Jenny Shmuel, Ph.D.
Blogs
IP Law Essentials
Blog
May 21, 2020
Overview of Approaches to Compulsory Licensing
Authors: Cheryl Wang, Brian D. Coggio, Sushil Iyer, Ph.D.
Blogs
IP Law Essentials
Blog
May 1, 2020
Where Juries Come From
Authors: Cheryl Wang, Katherine Reardon, Douglas E. McCann
IP Law Essentials
Blog
April 20, 2020
A Biosimilar’s Guide to the BPCIA Patent Dance: Five Key Questions for Every Biosimilar Applicant to Consider
Authors: Kayleigh E. McGlynn, Cheryl Wang, Jenny Shmuel, Ph.D.
IP Litigation
Life Sciences
Blog
March 20, 2020
Insulin and Other Biological Products Previously Regulated as “Drugs” Transition to Biologics Regulation on March 23, 2020
Authors: Cheryl Wang, Jenny Shmuel, Ph.D.
Life Sciences
Blog
February 7, 2020
Increasing Competition in the Biologic Market Through Truthful Advertising
Authors: Cheryl Wang, Jenny Shmuel, Ph.D.
Life Sciences
News
January 16, 2019
Fish & Richardson Grows Firm With 14 Associates
Press Release
News
load more topics
TOP